BLOOMFIELD, Conn., Jan. 14, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2024 financial results on Thursday, January 30, 2025, and will host a conference call the same day.
Fourth quarter 2024 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:
Live Call
(888) 566-1889 (Domestic)
(773) 799-3989 (International)
Passcode: 01302025
Replay
(800) 819-5739 (Domestic)
(203) 369-3350 (International)
It is strongly suggested that participants dial in to the conference call by 8:15 a.m. ET on January 30. A replay of the call will be available from 12:30 p.m. ET on January 30 until 11:59 p.m. ET on February 13, 2025. Additionally, the conference call will be available on a live internet webcast at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website. Please note that this feature will be in listen-only mode.
A copy of the company's news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section at https://investors.thecignagroup.com/overview/default.aspx, no later than 6:30 a.m. ET on January 30.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has approximately 184 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$304.35 |
| Daily Change: | 3.40 1.13 |
| Daily Volume: | 1,108,116 |
| Market Cap: | US$81.240B |
June 12, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
